RGLS Stock Summary and Trading Ideas (Regulus Therapeutics | NASDAQ:RGLS)

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Regulus Therapeutics trades on the NASDAQ stock market under the symbol RGLS.

As of April 19, 2024, RGLS stock price declined to $2.13 with 101,771 million shares trading.

RGLS has a beta of 1.35, meaning it tends to be more sensitive to market movements. RGLS has a correlation of 0.04 to the broad based SPY ETF.

RGLS has a market cap of $139.44 million. This is considered a Micro Cap stock.

In the last 3 years, RGLS stock traded as high as $15.45 and as low as $.76.

The top ETF exchange traded funds that RGLS belongs to (by Net Assets): VTI, VXF.

RGLS has outperformed the market in the last year with a return of +73.2%, while the SPY ETF gained +21.6%. In the last 3 month period, RGLS beat the market returning +74.6%, while SPY returned +4.6%. However, in the most recent 2 weeks RGLS has underperformed the stock market by returning -15.5%, while SPY returned -3.2%.

RGLS support price is $2.09 and resistance is $2.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RGLS stock will trade within this expected range on the day.